The Directorate General of Foreign Trade on 10th January 2022has imposed restriction on export of anticoagulant enoxaparin and intravenous immunoglobulin (IVIG) active pharmaceutical ingredients and their formulations to ensure their adequate supply in the domestic market.
Exporters of these products must now obtain an authorization or a license for their outgoing shipments.
Enoxaparin is being used for remedial mitigation of Covid associated coagulopathy (CAC). Patients with Covid-19 are at high threat of developing a venous thromboembolism (VTE). Studies have suggested that enoxaparin significantly reduces venous thromboembolism and is also associated with reduced all-cause mortality.
IVIG is one of the alternative treatments for Covid-19 patients. It is considered a therapeutic option for hyper inflammation in patients with severe Covid-19.
